表紙:男性不妊症の世界市場:市場規模、シェア、動向分析 - 検査タイプ(DNA断片化、酸化ストレス測定、顕微鏡検査)、治療法、地域別
市場調査レポート
商品コード
515309

男性不妊症の世界市場:市場規模、シェア、動向分析 - 検査タイプ(DNA断片化、酸化ストレス測定、顕微鏡検査)、治療法、地域別

Male Infertility Market Size, Share & Trends Analysis Report By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination), By Treatment, By Region, And Segment Forecasts, 2020 - 2027

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 100 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.28円
男性不妊症の世界市場:市場規模、シェア、動向分析 - 検査タイプ(DNA断片化、酸化ストレス測定、顕微鏡検査)、治療法、地域別
出版日: 2020年04月07日
発行: Grand View Research, Inc.
ページ情報: 英文 100 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の男性不妊症市場は、2020年から2027年にかけて4.7%のCAGRで推移し、市場規模は2027年までに50億3,000万米ドルに達すると予測されています。診断検査の技術的進歩や、男性不妊症の増加、肥満人口の増加、原因となる生活習慣病などが当市場の成長を促進する見通しです。検査タイプ別では、DNA断片化が2019年に最大セグメントとして台頭し、予測期間においても優勢を維持する見込みです

当レポートでは、世界の男性不妊症市場を調査し、市場の概要、検査タイプ・治療法・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 調査手法と範囲

  • 市場区分と範囲
  • 調査手法
  • 情報調達
  • 情報またはデータ分析
  • 市場形成と検証
  • モデル詳細
  • 二次情報源のリスト
  • 調査目的

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメントの見通し
  • 競合考察
  • 市場展望

第3章 市場変数・傾向・範囲

  • 市場系統の見通し
  • 市場セグメンテーション
  • 浸透と成長の見通しマッピング
  • ビジネス環境分析ツール
  • 臨床試験分析

第4章 男性不妊症市場の分析:検査タイプ別

  • 市場シェア:検査タイプ別(実績値・予測値)
  • セグメントダッシュボード
  • 市場規模:検査タイプ別(実績値・予測値)
    • DNA断片化
    • 酸化ストレス測定
    • 顕微鏡検査
    • 精子凝集試験
    • コンピュータ支援精子解析
    • 卵精子侵入試験
    • その他

第5章 男性不妊症市場の分析:治療法別

  • 市場シェア:治療法別(実績値・予測値)
  • セグメントダッシュボード
  • 市場規模:治療法別(実績値・予測値)
    • 生殖補助医療(ART)& 精索静脈瘤手術
    • 投薬

第6章 男性不妊症市場の分析:地域別

  • 市場シェア:地域別(実績値・予測値)
  • セグメントダッシュボード
  • 地域市場のスナップショット
  • SWOT分析:地域別
  • 市場動向と市場規模(実績値・予測値)
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ

第7章 競争分析

  • 戦略的フレームワーク/企業区分
  • ベンダー情勢
  • 企業の市場ポジション分析(地理的プレゼンス、製品ポートフォリオ、戦略的取り組み)
  • 企業プロファイル
    • EMD Serono, Inc.
    • Endo International plc
    • Sanofi
    • Bayer Group
    • SCSA Diagnostics
    • Halotech DNA SL
    • Intas Pharmaceuticals Ltd.
    • Aytu BioScience, Inc.
    • Cadila Pharmaceuticals
    • Vitrolife

第8章 推奨事項

図表

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 North America Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 3 North America Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 4 North America Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 5 U.S. Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 6 U.S. Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 7 Canada Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 8 Canada Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 9 Europe Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 10 Europe Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 11 Europe Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 12 U.K. Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 13 U.K. Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 14 Germany Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 15 Germany Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 16 Asia Pacific Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 17 Asia Pacific Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 18 Asia Pacific Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 19 Japan Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 20 Japan Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 21 China Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 22 China Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 23 Latin America Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 24 Latin America Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 25 Latin America Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 26 Brazil Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 27 Brazil Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 28 Mexico Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 29 Mexico Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 30 MEA Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 31 MEA Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 32 MEA Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 33 South Africa Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 34 South Africa Male Infertility market, by treatment, 2015 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market formulation & validation
  • FIG. 8 Male infertility market outlook, 2019 (USD Million)
  • FIG. 9 Market trends & outlook
  • FIG. 10 Male infertility market segmentation
  • FIG. 11 Penetration & growth prospect mapping
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Market restraint relevance analysis (Current & future impact)
  • FIG. 14 Porter's five forces analysis
  • FIG. 15 PESTEL analysis
  • FIG. 16 Male infertility test market share analysis, 2019 & 2027
  • FIG. 17 Male infertility test market: Segment dashboard
  • FIG. 18 DNA fragmentation technique market, 2015 - 2027 (USD Million)
  • FIG. 19 Oxidative stress analysis market, 2015 - 2027 (USD Million)
  • FIG. 20 Microscopic examination market, 2015 - 2027 (USD Million)
  • FIG. 21 Sperm agglutination market, 2015 - 2027 (USD Million)
  • FIG. 22 Computer assisted semen analysis market, 2015 - 2027 (USD Million)
  • FIG. 23 Sperm penetration assay market, 2015 - 2027 (USD Million)
  • FIG. 24 Others market, 2015 - 2027 (USD Million)
  • FIG. 25 Male infertility treatment market share analysis, 2019 & 2027
  • FIG. 26 Male infertility treatment market: Segment dashboard
  • FIG. 27 ART & varicocele surgery market, 2015 - 2027 (USD Million)
  • FIG. 28 Medication market, 2015 - 2027 (USD Million)
  • FIG. 29 Male infertility regional market share analysis, 2019 & 2027
  • FIG. 30 Male infertility regional market: Segment dashboard
  • FIG. 31 Regional market place: Key takeaways
  • FIG. 32 SWOT analysis: North America
  • FIG. 33 SWOT analysis: Europe
  • FIG. 34 SWOT analysis: Asia Pacific
  • FIG. 35 SWOT analysis: Latin America
  • FIG. 36 SWOT analysis: MEA
  • FIG. 37 North America male infertility market, 2015 - 2027 (USD Million)
  • FIG. 38 U.S. male infertility market, 2015 - 2027 (USD Million)
  • FIG. 39 Canada male infertility market, 2015 - 2027 (USD Million)
  • FIG. 40 Europe male infertility market, 2015 - 2027 (USD Million)
  • FIG. 41 U.K. male infertility market, 2015 - 2027 (USD Million)
  • FIG. 42 Germany male infertility market, 2015 - 2027 (USD Million)
  • FIG. 43 Asia Pacific male infertility market, 2015 - 2027 (USD Million)
  • FIG. 44 Japan male infertility market, 2015 - 2027 (USD Million)
  • FIG. 45 China male infertility market, 2015 - 2027 (USD Million)
  • FIG. 46 Latin America male infertility market, 2015 - 2027 (USD Million)
  • FIG. 47 Brazil male infertility market, 2015 - 2027 (USD Million)
  • FIG. 48 Mexico male infertility market, 2015 - 2027 (USD Million)
  • FIG. 49 MEA male infertility market, 2015 - 2027 (USD Million)
  • FIG. 50 South Africa male infertility market, 2015 - 2027 (USD Million)
  • FIG. 51 Strategy framework
  • FIG. 52 Male infertility competitive landscape: Market position analysis (based on products, regional presence, and recent updates (2019))
目次
Product Code: GVR-1-68038-833-6

The global male infertility market size is expected to reach USD 5.03 billion by 2027, expanding at a CAGR of 4.7% over the forecast period, according to a new report by Grand View Research, Inc. Advancements in diagnostic tests and increasing infertility in males are some of the major factors driving the market for male infertility. In addition, lifestyle-associated diseases causing infertility, rising obesity, and growing aging population are likely to boost the market growth during the forecast period. In U.S., one-third of infertility cases are due to female factors, one third due to male factors, and the remaining one third is unknown.

DNA fragmentation technique emerged the largest test segment in the market in 2019 and is expected to maintain its lead during the forecast period. Increasing adoption in developed countries and high cost due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors driving the segment.

On the basis of treatment, the Assisted Reproductive Technology (ART) and Varicocele Surgery segment dominated the market for male infertility in 2019 due to its high success rate. Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are the most commonly used ARTs. Medications include hormonal therapy and corticosteroids, however they are effective in very few cases.

Partnerships and agreements among key manufacturers are expected to boost the market growth in the coming years. For instance, in July 2019, Vitrolife entered into a collaboration with Prime Tech for the development and exclusive marketing of the Piezo technique, for improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will initiate the regulatory approval procedures in various markets for the future commercialization of the technology.

Further key findings from the study suggest:

Based on test, DNA fragmentation technique dominated the market in 2019 and is estimated to witness significant growth over the forecast period

Oxidative stress analysis test is gaining popularity due to the accurate determination of reactive oxygen species. In March 2018, Aytu BioScience, Inc. received registration from COFEPRIS in Mexico for MiOXSYS System, which is used for diagnosing male infertility

Europe dominated the male infertility market in 2019 and is expected to maintain its lead during the forecast period due to high adoption of costlier treatment, strong diagnosis rate, and increased awareness

Asia Pacific is projected to witness substantial growth over the forecast period owing to increasing investment by several clinics and pharmaceutical companies and growing healthcare expenditure

Some key players of the market are Bayer Healthcare, Inc.; EMD Sereno; Aytu BioScience, Inc.; Halotech DNA SL; Intas Pharmaceuticals Ltd.; Cadila Healthcare Ltd.; Andrology Solutions; and SCSA diagnostics, Inc.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Test
    • 1.1.2 Treatment
    • 1.1.3 Regional Scope
    • 1.1.4 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis (Model 1)
    • 1.6.2 Volume price analysis (model 2)
  • 1.7 List of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective - 1
    • 1.8.2 Objective - 2

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Test
    • 2.2.2 Treatment
    • 2.2.3 Region
  • 2.3 Competitive Insights
  • 2.4 Male Infertility Market Outlook, 2019

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Market Segmentation
  • 3.3 Penetration & Growth Prospect Mapping
    • 3.3.1 Penetration Analysis
    • 3.3.2 Market driver analysis
      • 3.3.2.1 High Adoption of Assisted Reproductive Technology (ART)
      • 3.3.2.2 Increasing incidence of infertility
      • 3.3.2.3 Acquisitions, mergers, and partnerships in the market
      • 3.3.2.4 Technological advancements
    • 3.3.3 Market restraint analysis
      • 3.3.3.1 High cost of treatment
  • 3.4 Male Infertility Market: Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 PESTEL Analysis
  • 3.5 Clinical Trial Analysis

Chapter 4 Male Infertility Market: Test Analysis

  • 4.1 Male Infertility Test Market Share Analysis, 2019 & 2027
  • 4.2 Male Infertility Test Market: Segment Dashboard:
  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Test Segment
    • 4.3.1 DNA Fragmentation Technique
      • 4.3.1.1 DNA fragmentation technique market, 2015 - 2027 (USD Million)
    • 4.3.2 Oxidative Stress Analysis
      • 4.3.2.1 Oxidative stress analysis market, 2015 - 2027 (USD Million)
    • 4.3.3 Microscopic Examination
      • 4.3.3.1 Microscopic Examination market, 2015 - 2027 (USD Million)
    • 4.3.4 Sperm Agglutination
      • 4.3.4.1 Sperm agglutination market, 2015 - 2027 (USD Million)
    • 4.3.5 Computer Assisted Semen Analysis
      • 4.3.5.1 Computer assisted semen analysis market, 2015 - 2027 (USD Million)
    • 4.3.6 Sperm Penetration Assay
      • 4.3.6.1 Sperm penetration assay market, 2015 - 2027 (USD Million)
    • 4.3.7 Others
      • 4.3.7.1 Others market, 2015 - 2027 (USD Million)

Chapter 5 Male Infertility Market: Treatment Analysis

  • 5.1 Male Infertility Treatment Market Share Analysis, 2019 & 2027
  • 5.2 Male Infertility Treatment Market: Segment Dashboard:
  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Treatment Segment
    • 5.3.1 ART & Varicocele Surgery
      • 5.3.1.1 ART & varicocele surgery market, 2015 - 2027 (USD Million)
    • 5.3.2 Medication
      • 5.3.2.1 Medication market, 2015 - 2027 (USD Million)

Chapter 6 Male Infertility Market: Regional Analysis

  • 6.1 Male Infertility Regional Market Share Analysis, 2019 & 2027
  • 6.2 Male Infertility Regional Market: Segment Dashboard
  • 6.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
  • 6.4 SWOT Analysis, by Region
    • 6.4.1 North America
    • 6.4.2 Europe
    • 6.4.3 Asia Pacific
    • 6.4.4 Latin America
    • 6.4.5 MEA
  • 6.5 Market Size, & Forecasts, and Trend Analysis, 2015 to 2027
    • 6.5.1 North America
      • 6.5.1.1 North America male infertility market, 2015 - 2027 (USD Million)
      • 6.5.1.1.1 U.S.
      • 6.5.1.1.1.1 Regulatory & reimbursement scenario
      • 6.5.1.1.1.2 U.S. male infertility market, 2015 - 2027 (USD Million)
      • 6.5.1.1.2 Canada
      • 6.5.1.1.2.1 Regulatory & reimbursement scenario
      • 6.5.1.1.2.2 Canada male infertility market, 2015 - 2027 (USD Million)
    • 6.5.2 Europe
      • 6.5.2.1 Europe male infertility market, 2015 - 2027 (USD Million)
      • 6.5.2.1.1 U.K.
      • 6.5.2.1.1.1 Regulatory & reimbursement scenario
      • 6.5.2.1.1.2 U.K. male infertility market, 2015 - 2027 (USD Million)
      • 6.5.2.1.2 Germany
      • 6.5.2.1.2.1 Regulatory & reimbursement scenario
      • 6.5.2.1.2.2 Germany male infertility market, 2015 - 2027 (USD Million)
    • 6.5.3 Asia Pacific
      • 6.5.3.1 Asia Pacific male infertility market, 2015 - 2027 (USD Million)
      • 6.5.3.1.1 Japan
      • 6.5.3.1.1.1 Regulatory & reimbursement scenario
      • 6.5.3.1.1.2 Japan male infertility market, 2015 - 2027 (USD Million)
      • 6.5.3.1.2 China
      • 6.5.3.1.2.1 Regulatory & reimbursement scenario
      • 6.5.3.1.2.2 China male infertility market, 2015 - 2027 (USD Million)
    • 6.5.4 Latin America
      • 6.5.4.1 Latin America male infertility market, 2015 - 2027 (USD Million)
      • 6.5.4.1.1 Brazil
      • 6.5.4.1.1.1 Regulatory & reimbursement scenario
      • 6.5.4.1.1.2 Brazil male infertility market, 2015 - 2027 (USD Million)
      • 6.5.4.1.2 Mexico
      • 6.5.4.1.2.1 Regulatory & reimbursement scenario
      • 6.5.4.1.2.2 Mexico male infertility market, 2015 - 2027 (USD Million)
    • 6.5.5 Middle East and Africa (MEA)
      • 6.5.5.1 MEA male infertility market, 2015 - 2027 (USD Million)
      • 6.5.5.1.1 South Africa
      • 6.5.5.1.1.1 Regulatory & reimbursement scenario
      • 6.5.5.1.1.2 South Africa male infertility market, 2015 - 2027 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
  • 7.2 Vendor Landscape
    • 7.2.1 Strategy Mapping
    • 7.2.2 Launch of New Products
    • 7.2.3 Merger and Acquisition
    • 7.2.4 Product Approvals
  • 7.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Strategic Initiatives)
  • 7.4 Company Profiles
    • 7.4.1 EMD Serono, Inc.
      • 7.4.1.1 Company overview
      • 7.4.1.2 Financial performance
      • 7.4.1.3 Product benchmarking
      • 7.4.1.4 Strategic initiatives
    • 7.4.2 Endo International plc
      • 7.4.2.1 Company overview
      • 7.4.2.2 Financial performance
      • 7.4.2.3 Product benchmarking
      • 7.4.2.4 Strategic initiatives
      • 7.4.2.5 SWOT analysis
    • 7.4.3 Sanofi
      • 7.4.3.1 Company overview
      • 7.4.3.2 Financial performance
      • 7.4.3.3 Product benchmarking
      • 7.4.3.4 Strategic initiatives
      • 7.4.3.5 SWOT Analysis
    • 7.4.4 Bayer Group
      • 7.4.4.1 Company overview
      • 7.4.4.2 Financial performance
      • 7.4.4.3 Product benchmarking
      • 7.4.4.4 Strategic initiatives
      • 7.4.4.5 SWOT analysis
    • 7.4.5 SCSA Diagnostics
      • 7.4.5.1 Company overview
      • 7.4.5.2 Product benchmarking
    • 7.4.6 Andrology Solutions
      • 7.4.6.1 Company overview
      • 7.4.6.2 Product benchmarking
    • 7.4.7 Halotech DNA SL
      • 7.4.7.1 Company overview
      • 7.4.7.2 Product benchmarking
      • 7.4.7.3 Strategic initiatives
    • 7.4.8 Intas Pharmaceuticals Ltd.
      • 7.4.8.1 Company overview
      • 7.4.8.2 Financial performance
      • 7.4.8.3 Product benchmarking
      • 7.4.8.4 Strategic initiatives
      • 7.4.8.5 SWOT analysis
    • 7.4.9 Aytu BioScience, Inc.
      • 7.4.9.1 Company overview
      • 7.4.9.2 Financial performance
      • 7.4.9.3 Product Benchmarking
      • 7.4.9.4 Strategic initiatives
      • 7.4.9.5 SWOT Analysis
    • 7.4.10 Cadila Pharmaceuticals
      • 7.4.10.1 Company overview
      • 7.4.10.2 Product benchmarking
      • 7.4.10.3 Strategic initiatives
    • 7.4.11 Vitrolife
      • 7.4.11.1 Company overview
      • 7.4.11.2 Financial performance
      • 7.4.11.3 Product benchmarking
      • 7.4.11.4 Strategic initiatives
      • 7.4.11.5 SWOT Analysis

Chapter 8 Recommendations